
TOI Stock Forecast & Price Target
TOI Analyst Ratings
Bulls say
Oncology Institute is projected to have a positive outlook for several reasons. The company has a strong focus on revenue-generating segments such as Specialty Pharmacy and Clinical Trials, which make up the majority of its operating segments. It also offers a wide range of oncology services to its patients, including clinical trials enrollment, making it a valuable and comprehensive resource in the healthcare industry. Additionally, with a solid performance and growth potential, Oncology Institute presents a promising investment opportunity for the future.
Bears say
Oncology Institute is a growing company that offers oncology care services, but its reliance on IV-infused specialty pharmacy and other high-cost treatments may lead to increased financial pressure and limit its ability to invest in growth. The company also has a heavy debt load and limited cash reserves, which could create refinancing risks and restrict investments. In addition, Oncology Institute faces competition from various oncology providers and risks associated with changes in healthcare legislation and reimbursement pressures. Overall, the company is trading at reasonable valuation relative to its peers, but may face challenges in sustaining its growth and profitability.
This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.
TOI Analyst Forecast & Price Prediction
Start investing in TOI
Order type
Buy in
Order amount
Est. shares
0 shares